




**Abeona Therapeutics** (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company's multi-platform expertise across the research, development, manufacture, and discovery of novel gene and cell therapies has it uniquely positioned to bring new medicines to patients in need.

### Our Commitment

Our strategy to harness the promise of genetic medicine to transform the lives of patients is inspired by our vision, to realize a world where cure is the new standard of care. Our mission is to work together to deliver gene and cell therapies for people impacted by serious diseases.

### Advancing a Robust Pipeline of Gene & Cell Therapies



### Manufacturing GMP-compliant Gene and Cell Therapies

Abeona is underpinned by The Elisa Linton Center for Rare Disease Therapies, its fully-operational, GMP-compliant manufacturing facility in Cleveland, OH, which may speed the delivery of gene and cell therapies to patients.

- Manufacturing product for the pivotal Phase 3 EB-101 VIITAL™ study.
- Capable of clinical and commercial production of Abeona's AAV-based gene therapies.
- Established CMC capabilities in process/assay development, validated and governed by comprehensive quality systems.
- Strengthened control of supply, quality, timelines, and costs and reduces the risks of outsourcing this highly-specialized work.

### Fostering the Next Generation of AAV Gene Therapy

Abeona is developing the AIM™ Vector Platform, the next-generation AAV capsids for use in gene therapies, being developed to utilize AAV biology to selectively target delivery of genetic payloads to the central nervous system, lungs, eye, muscle, liver and other tissues. AIM™ vectors are non-replicating and have shown the potential to evade the body's immune responses to naturally-occurring AAV vectors that can interfere with therapeutic efficacy. The Company's AIM™ library contains more than 100 capsids with tissue tropisms selected for their potential to target a wide range of organs and multiple routes of delivery.